Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...

On Wednesday, Adaptimmune Therapeutics plc (NASDAQ:ADAP) received an upgrade from Jones Trading, shifting from a Hold to a Buy rating. The firm has also set a new price target ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zoetis (ZTS – Research Report), Terns ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI – Research Report), Vertex Pharmaceuticals (VRTX – ...

European equities traded in the US as American depositary receipts were lower late Friday morning, declining 0.22% to 1,373.53 on the S&P Europe Select ADR Index. From continental Europe, the gainers ...

After hours: 7:48:01 p.m. EST ...

SEC Filings provided by EDGAR Online, Inc.

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Research reports are not currently available for ADAP.